Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00448071
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:34:49.939987+00:00
Published At
2007-03-15T00:00:00+00:00
Record Updated At
2007-03-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hypotension", "End Stage Renal Disease", "Intra Dialytic Hypotension"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2007-03-15"
protocolSection.identificationModule.nctId
"NCT00448071"
protocolSection.identificationModule.officialTitle
"A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Hypotension (protocolSection.conditionsModule.conditions)
  • End Stage Renal Disease (protocolSection.conditionsModule.conditions)
  • Intra Dialytic Hypotension (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.